PDF
CAR-T-cell products in solid tumors: Progress, challenges, and strategies
Kewen Qian, Guangyao Li, Shuyi Zhang, Wenyan Fu, Tian Li, Jian Zhao, Changhai Lei, Yuqing Wang, Shi Hu
PDF
CAR-T-cell products in solid tumors: Progress, challenges, and strategies
T cells engineered to express chimeric antigen receptors (CARs) with specificity toward tumor cells have led to promising outcomes in patients with hematological malignancies. Nevertheless, the application of CAR-T cell therapy in solid tumors encounters several obstacles. These include tumor heterogeneity and immune escape, T cell exhaustion and restricted infiltration into the tumors that affect the therapeutic efficacy of CAR-T cells, as well as “on-target, off-tumor” toxicities that can lead to severe and even fatal adverse events. In recent years, clinical trials and new approaches of CAR-T cell therapy for solid tumors have made certain progress. Here, we update the outcomes of related clinical trials and summarize engineered strategies aiming to improve the efficacy and therapeutic safety of CAR-T cells based on experimental and clinical studies.
cancer therapy / CAR-T / chimeric antigen receptor / solid tumor / tumor microenvironment
/
| 〈 |
|
〉 |
AI Summary
